Our evidence that mutations in BRCA1/2 and CHEK2 predispose Polish women to DCIS, should encourage clinicians to refer patients with DCIS for genetic counselling and testing more commonly. The gene discussed is BRCA1; the disease is ductal breast carcinoma in situ.